A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: A pilot study

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 163-166

  Biederman, Joseph ^a,b   Mick, Eric ^a,b   Faraone, Stephen ^c   Hammerness, Paul ^a,b   Surman, Craig ^a,b   Harpold, Theresa ^a,b   Dougherty, Meghan ^a   Aleardi, Megan ^a   Spencer, Thomas ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE HYDROGEN BROMIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRY EYE; DRY SKIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; XEROSTOMIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PILOT PROJECTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 33646688418     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000204139.20417.8a     Document Type: Article

References (14)

1. Spencer T. Adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:XI-XII.
2. Kessler RC. Prevalence of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication (NCS-R). In: Annual Meeting of the American Psychiatric Association. New York, NY: American Psychiatric Association; 2004;6.
3. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775-782.
4. Meek WH, Church RM. Cholinergic modulation of the content of temporal memory. Behav Neurosci. 1987;101:457-464.
5. Peeke SC, Peeke HV. Attention, memory, and cigarette smoking. Psychopharmacology. 1984;84:205-216.
6. Jones GM, Sahakian BJ, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimerz's disease. Psychopharmacology. 1992;108:485-494.
7. Wesnes K, Warburton DM. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology. 1984;82:338-342.
8. Biederman J, Monuteaux M, Seidman L, et al. Impact of executive function deficits and ADHD on academic outcomes in children. J Consult Clin Psychol. 2004;72:757-766.
9. Levin ED, Westman EC, Stein RM, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol. 1994;14:41-49.
10. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156:1931-1937.
11. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-538.
12. Spencer T, Adler L. Diagnostic approaches to adult attention-deficit/ hyperactivity disorder. Primary Psychiatry. 2004;11:49-56.
13. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
14. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998;155:693-695.